RxDoctor Payments Data

Todd Markwalter

Family · Johnson City, TNNPI 1700894276

Payments from drug & device makers

$1,079in general payments, 2019–2025

Across 30 payments — averaging $35.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$286
  • Teva Pharmaceuticals USA, Inc.$243
  • UCB, Inc.$213
  • Acadia Pharmaceuticals Inc$201
  • Sumitomo Pharma America, Inc.$82
  • Otsuka America Pharmaceutical, Inc.$42
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$1,079100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,079 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$85,413
Medicare patients
124
Services billed
1,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron63$14,394
EliquisApixaban57$8,430
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen509$6,481
Xtampza ErOxycodone Myristate29$5,738
Gabapentin624$4,906
Furosemide673$3,121
Levothyroxine Sodium469$2,556
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,391
Potassium Chloride218$2,385
Mirtazapine225$1,824
Lacosamide37$1,769
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen217$1,652
Pantoprazole Sodium208$1,411
Atorvastatin Calcium322$1,338
Omeprazole210$1,315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$82$14,39463 claims
Teva Pharmaceuticals USA, Inc.Albuterol Sulfate$243$38119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →